Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320776 | 0.92 | RET (0.56) | RETABCG2ABCB1ABCC1SYK | |
| SCHEMBL14320369 | 0.91 | ABCG2 (0.62) | ABCG2ABCB1ABCC1 | |
| SCHEMBL14320463 | 0.90 | SYK (0.56) | RETABCG2ABCB1ABCC1SYK | |
| SCHEMBL14321350 | 0.85 | ABCG2 (0.65) | ABCG2ABCB1ABCC1SYK | |
| SCHEMBL14321014 | 0.85 | ABCG2 (0.57) | ABCG2ABCB1ABCC1 | |
| SCHEMBL28086152 | 0.85 | ABCG2 (0.67) | ABCG2ABCB1ABCC1 | |
| SCHEMBL14320419 | 0.84 | ABCG2 (0.68) | ABCG2ABCB1ABCC1 | |
| SCHEMBL14321184 | 0.83 | KDM1A (0.54) | ABCG2ABCB1ABCC1KDR | |
| SCHEMBL14320631 | 0.83 | ABCG2 (0.53) | ABCG2ABCB1ABCC1 | |
| SCHEMBL14320693 | 0.83 | ABCG2 (0.65) | ABCG2ABCB1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | claimed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | claimed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | claimed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | RET 282/4885ABCG2 3810/4885ABCB1 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.